SE9801474D0 - Quinoline Derivatives - Google Patents

Quinoline Derivatives

Info

Publication number
SE9801474D0
SE9801474D0 SE9801474A SE9801474A SE9801474D0 SE 9801474 D0 SE9801474 D0 SE 9801474D0 SE 9801474 A SE9801474 A SE 9801474A SE 9801474 A SE9801474 A SE 9801474A SE 9801474 D0 SE9801474 D0 SE 9801474D0
Authority
SE
Sweden
Prior art keywords
propyl
iso
butyl
formula
ethyl
Prior art date
Application number
SE9801474A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9801474A priority Critical patent/SE9801474D0/xx
Publication of SE9801474D0 publication Critical patent/SE9801474D0/xx
Priority to US09/296,519 priority patent/US6077851A/en
Priority to PT99947036T priority patent/PT1073639E/pt
Priority to EP99947036A priority patent/EP1073639B1/en
Priority to PL99343420A priority patent/PL190441B1/pl
Priority to JP2000545838A priority patent/JP4045069B2/ja
Priority to OA1200000301A priority patent/OA11547A/en
Priority to CZ20003849A priority patent/CZ297439B6/cs
Priority to PCT/SE1999/000676 priority patent/WO1999055678A1/en
Priority to TR2000/03061T priority patent/TR200003061T2/xx
Priority to MEP-2000-612A priority patent/ME00870B/me
Priority to CA002329788A priority patent/CA2329788C/en
Priority to NZ506641A priority patent/NZ506641A/en
Priority to APAP/P/2000/001933A priority patent/AP1293A/en
Priority to UA2000085078A priority patent/UA60354C2/uk
Priority to IL13816099A priority patent/IL138160A0/xx
Priority to IDW20002183A priority patent/ID26277A/id
Priority to KR1020007011944A priority patent/KR100571534B1/ko
Priority to DE69904162T priority patent/DE69904162T2/de
Priority to YUP-612/00A priority patent/RS50029B/sr
Priority to CN99805581A priority patent/CN1113057C/zh
Priority to ES99947036T priority patent/ES2188242T3/es
Priority to HU0102084A priority patent/HU227709B1/hu
Priority to BRPI9909925-0A priority patent/BR9909925B1/pt
Priority to RU2000129672/04A priority patent/RU2197481C2/ru
Priority to AU43013/99A priority patent/AU747550B2/en
Priority to AT99947036T priority patent/ATE228505T1/de
Priority to DK99947036T priority patent/DK1073639T3/da
Priority to EEP200000613A priority patent/EE04275B1/xx
Priority to IL138160A priority patent/IL138160A/en
Priority to IS5615A priority patent/IS2082B/is
Priority to ZA200004601A priority patent/ZA200004601B/en
Priority to NO20005254A priority patent/NO315606B1/no
Priority to HR20000726A priority patent/HRP20000726B1/xx
Priority to HK01105489A priority patent/HK1036618A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9801474A 1998-04-27 1998-04-27 Quinoline Derivatives SE9801474D0 (sv)

Priority Applications (35)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives
US09/296,519 US6077851A (en) 1998-04-27 1999-04-22 Quinoline derivatives
EEP200000613A EE04275B1 (et) 1998-04-27 1999-04-26 Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
IDW20002183A ID26277A (id) 1998-04-27 1999-04-26 Turunan-turunan kuinolina
YUP-612/00A RS50029B (sr) 1998-04-27 1999-04-26 Derivati hinolina
PL99343420A PL190441B1 (pl) 1998-04-27 1999-04-26 Nowe pochodne 1-metylo-2-okso-chinolino-3-karboksyamidu zawierające je kompozycje farmaceutyczne oraz sposób ich wytwarzania
JP2000545838A JP4045069B2 (ja) 1998-04-27 1999-04-26 キノリン誘導体
OA1200000301A OA11547A (en) 1998-04-27 1999-04-26 Quinoline derivatives.
CZ20003849A CZ297439B6 (cs) 1998-04-27 1999-04-26 Deriváty chinolinu
PCT/SE1999/000676 WO1999055678A1 (en) 1998-04-27 1999-04-26 Quinoline derivatives
TR2000/03061T TR200003061T2 (tr) 1998-04-27 1999-04-26 Kinolin türevleri
MEP-2000-612A ME00870B (me) 1998-04-27 1999-04-26 Derivati hinolina
CA002329788A CA2329788C (en) 1998-04-27 1999-04-26 Quinoline derivatives
NZ506641A NZ506641A (en) 1998-04-27 1999-04-26 Quinoline derivatives useful in the treatment of autoimmune disorders
APAP/P/2000/001933A AP1293A (en) 1998-04-27 1999-04-26 Quinoline derivatives.
UA2000085078A UA60354C2 (uk) 1998-04-27 1999-04-26 Похідні хіноліну, спосіб їх одержання (варіанти) та спосіб лікування ссавців
IL13816099A IL138160A0 (en) 1998-04-27 1999-04-26 Quinoline derivatives
PT99947036T PT1073639E (pt) 1998-04-27 1999-04-26 Derivados de quinolina
KR1020007011944A KR100571534B1 (ko) 1998-04-27 1999-04-26 퀴놀린 유도체
DE69904162T DE69904162T2 (de) 1998-04-27 1999-04-26 Chinolinderivate
EP99947036A EP1073639B1 (en) 1998-04-27 1999-04-26 Quinoline derivatives
CN99805581A CN1113057C (zh) 1998-04-27 1999-04-26 喹啉衍生物
ES99947036T ES2188242T3 (es) 1998-04-27 1999-04-26 Derivados de quinolina.
HU0102084A HU227709B1 (en) 1998-04-27 1999-04-26 Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
BRPI9909925-0A BR9909925B1 (pt) 1998-04-27 1999-04-26 derivados de quinolina, composições farmacêuticas, e, processo para a fabricação de derivados de quinolina.
RU2000129672/04A RU2197481C2 (ru) 1998-04-27 1999-04-26 Производные хинолина
AU43013/99A AU747550B2 (en) 1998-04-27 1999-04-26 Quinoline derivatives
AT99947036T ATE228505T1 (de) 1998-04-27 1999-04-26 Chinolinderivate
DK99947036T DK1073639T3 (da) 1998-04-27 1999-04-26 Chinolinderivater
IL138160A IL138160A (en) 1998-04-27 2000-08-30 Quinoline derivatives
IS5615A IS2082B (is) 1998-04-27 2000-08-31 Kvínólínafleiður
ZA200004601A ZA200004601B (en) 1998-04-27 2000-09-01 Quinoline derivatives.
NO20005254A NO315606B1 (no) 1998-04-27 2000-10-19 Kinolinderivater
HR20000726A HRP20000726B1 (en) 1998-04-27 2000-10-26 Quinoline derivatives
HK01105489A HK1036618A1 (en) 1998-04-27 2001-08-07 Quinoline derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives

Publications (1)

Publication Number Publication Date
SE9801474D0 true SE9801474D0 (sv) 1998-04-27

Family

ID=20411103

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives

Country Status (33)

Country Link
EP (1) EP1073639B1 (is)
JP (1) JP4045069B2 (is)
KR (1) KR100571534B1 (is)
CN (1) CN1113057C (is)
AP (1) AP1293A (is)
AT (1) ATE228505T1 (is)
AU (1) AU747550B2 (is)
BR (1) BR9909925B1 (is)
CA (1) CA2329788C (is)
CZ (1) CZ297439B6 (is)
DE (1) DE69904162T2 (is)
DK (1) DK1073639T3 (is)
EE (1) EE04275B1 (is)
ES (1) ES2188242T3 (is)
HK (1) HK1036618A1 (is)
HR (1) HRP20000726B1 (is)
HU (1) HU227709B1 (is)
ID (1) ID26277A (is)
IL (2) IL138160A0 (is)
IS (1) IS2082B (is)
ME (1) ME00870B (is)
NO (1) NO315606B1 (is)
NZ (1) NZ506641A (is)
OA (1) OA11547A (is)
PL (1) PL190441B1 (is)
PT (1) PT1073639E (is)
RS (1) RS50029B (is)
RU (1) RU2197481C2 (is)
SE (1) SE9801474D0 (is)
TR (1) TR200003061T2 (is)
UA (1) UA60354C2 (is)
WO (1) WO1999055678A1 (is)
ZA (1) ZA200004601B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
EP1828160B1 (en) 2004-12-21 2011-12-14 Merck Serono SA Sulfonyl amino cyclic derivatives and use thereof as mmp inhibitors
JP4950070B2 (ja) 2005-01-31 2012-06-13 メルク セローノ ソシエテ アノニム Ｎ−ヒドロキシアミド誘導体及びその使用
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
AU2006286489B2 (en) 2005-09-01 2012-08-09 Ares Trading S.A. Treatment of optic neuritis
CA2625287C (en) 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
ZA200810790B (en) * 2006-06-12 2010-03-31 Teva Pharma Stable laquinimod preparations
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR20160079147A (ko) * 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
MX2012001333A (es) * 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
ES2586843T3 (es) 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Tratamiento de trastornos relacionados con BDNF usando laquinimod
PL2542080T3 (pl) * 2010-03-03 2017-02-28 Teva Pharmaceutical Industries Ltd. Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu
SI2542079T1 (sl) * 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
AU2011223692A1 (en) * 2010-03-03 2012-10-25 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
MX2013000332A (es) * 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
PL2590949T3 (pl) * 2010-07-09 2016-06-30 Active Biotech Ab Sposób wytwarzania chinolino-3-karboksyamidów
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
AR089862A1 (es) * 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
SG11201505818WA (en) * 2013-02-15 2015-08-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
CA2961978C (en) 2014-09-23 2023-03-14 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
PL3180005T3 (pl) 2014-11-19 2018-06-29 Active Biotech Ab Chinolinokarboksyamidy do stosowania w leczeniu białaczki
BR112022009192A2 (pt) 2019-12-19 2022-07-26 Active Biotech Ab Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto
IL295780A (en) 2020-03-03 2022-10-01 Active Biotech Ab Tesquinimov or a pharmaceutically acceptable salt thereof for use in combination therapy
EP4153576A4 (en) * 2020-05-21 2024-06-19 Stemsynergy Therapeutics Inc NOTCH INHIBITORS AND USES THEREOF
JP2023535021A (ja) 2020-07-23 2023-08-15 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質
CA3204120A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
AU2022281056A1 (en) 2021-05-25 2023-11-30 Active Biotech Ab A plurality of tasquinimod particles and use thereof
CA3221689A1 (en) 2021-07-02 2023-01-05 Hans Wannman A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
ATE228505T1 (de) 2002-12-15
NO20005254L (no) 2000-12-27
UA60354C2 (uk) 2003-10-15
NO20005254D0 (no) 2000-10-19
ZA200004601B (en) 2002-02-27
AP2000001933A0 (en) 2000-12-31
PT1073639E (pt) 2003-04-30
ID26277A (id) 2000-12-14
RU2197481C2 (ru) 2003-01-27
IL138160A0 (en) 2001-10-31
WO1999055678A1 (en) 1999-11-04
ES2188242T3 (es) 2003-06-16
IL138160A (en) 2006-04-10
DE69904162D1 (de) 2003-01-09
RS50029B (sr) 2008-11-28
EE200000613A (et) 2002-04-15
NZ506641A (en) 2002-03-28
PL190441B1 (pl) 2005-12-30
AU4301399A (en) 1999-11-16
HRP20000726A2 (en) 2001-04-30
PL343420A1 (en) 2001-08-13
KR100571534B1 (ko) 2006-04-14
TR200003061T2 (tr) 2001-01-22
IS2082B (is) 2006-02-15
DE69904162T2 (de) 2003-08-21
HUP0102084A3 (en) 2002-12-28
AP1293A (en) 2004-08-30
HUP0102084A2 (hu) 2001-11-28
HRP20000726B1 (en) 2009-04-30
CZ297439B6 (cs) 2006-12-13
YU61200A (sh) 2003-07-07
JP4045069B2 (ja) 2008-02-13
AU747550B2 (en) 2002-05-16
BR9909925B1 (pt) 2010-09-21
NO315606B1 (no) 2003-09-29
CN1298393A (zh) 2001-06-06
CZ20003849A3 (cs) 2001-03-14
IS5615A (is) 2000-08-31
DK1073639T3 (da) 2003-03-24
EE04275B1 (et) 2004-04-15
CA2329788A1 (en) 1999-11-04
BR9909925A (pt) 2001-01-09
CA2329788C (en) 2004-11-23
HK1036618A1 (en) 2002-01-11
ME00870B (me) 2008-11-28
EP1073639A1 (en) 2001-02-07
JP2002513006A (ja) 2002-05-08
OA11547A (en) 2004-05-24
CN1113057C (zh) 2003-07-02
HU227709B1 (en) 2011-12-28
EP1073639B1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
SE9801474D0 (sv) Quinoline Derivatives
SE9802549D0 (sv) Quinoline derivatives
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
AP1425A (en) Quinoline derivatives.
ATE37179T1 (de) Dihydropyridazinone.
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
EE200100513A (et) Rakkude adhesiooni inhibeerivad põletikuvastased ja immunosupressiivsed ühendid
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
FI955085A (fi) Uudet diosmetiiniyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EA200101050A1 (ru) Замещенные бензолактамные соединения
NO833918L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolderivater
SE0400440D0 (sv) Novel Cinnamic Amides
DE60009932D1 (de) 5-aminoalkyl- und 5-aminocarbonylsubstituierte indole
FI834789A0 (fi) Foerfarande foer framstaellning av 1,1-difenylpropanolderivat
SE8405332L (sv) 2h-azeto (2,1-a)-isokinolinderivat, forfarande for deras framstellning och farmaceutiska kompositioner innehallande dem
SE9902147L (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma
RU92016560A (ru) Замещенные бензоимидазолы, фармацевтическая композиция, способ ингибирования или лечения и способ их получения и применение